Wolfe Research Reiterates Peerperform Rating on Alnylam Pharmaceuticals (ALNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiranā¼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
August 30, 2024 6:00 AM EDTIn the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period and up to Month 42, Respectively
In the Monotherapy Population, Reduced Composite Primary Endpoint by 33% and All-Cause Mortality up to Month 42 by 35%
Strong Trends of Additive Efficacy on Top of Tafamidis Across Primary and Secondary Endpoints
Demonstrated Statistically Significant Benefits on Multiple Measures of Disease Progression
Encouraging Safety and Tolerability Profile, Consistent with Established Profile... More
